To assess the in vivo short-term antiretroviral effect of hydroxyurea in human immunodeficiency virus (HIV) -infected persons chronically treated with didanosine (ddI), 26 patients with CD4 cell counts between 100 and 350 were enrolled in a 12-week, open-label pilot study and randomly assigned to receive 500 or 1000 mg/day hydroxyurea. Clinical status, laboratory toxicities, CD4 lymphocyte count, and HIV RNA plasma virus load were assessed weekly. Median declines from baseline of 0.02 and 0.63 log 10 HIV-1 RNA copies/mL of plasma were observed for the 500-and 1000-mg/day groups, respectively (P Å .02). CD4 cell counts did not change significantly with the addition of hydroxyurea; however, a small but statistically significant decrease in counts was observed during the washout phase. Both doses of hydroxyurea were well-tolerated. These results demonstrate a substantial decrease in plasma virus load when 1000 mg of hydroxyurea is administered over 1 month as adjunctive therapy to ddI among HIV-infected persons with 100 -350 CD4 cells/mm 3 .
To date, nucleoside analogues remain the cornerstone of to the enhanced uptake of ddATP, the active metabolite of ddI [9] . An alternative hypothesis suggests that hydroxyurea can treatment against human immunodeficiency virus (HIV) infection. Prolongation of the disease-free interval and survival have act as a chelating agent of metalloproteins essential for viral replication [10] . Regardless of its ultimate mechanism of acbeen clearly documented using zidovudine [1, 2] and didanosine (ddI) monotherapy [3, 4] and more recently when combition, hydroxyurea in combination with ddI substantially decreases viral replication in vitro on activated and quiescent nations of ddI and zidovudine or zidovudine and zalcitabine [5, 6] were used. Unfortunately, the benefits associated with peripheral blood mononuclear cells [8] .
Hydroxyurea's clinical safety profile is well-characterized, currently available antiretroviral therapies appear to be timelimited, so the search for newer therapeutic strategies must as it has been in use for a number of years for the treatment of a variety of neoplasms [11] . More recently, this compound continue.
In vitro studies have suggested that hydroxyurea can inhibit was shown to be of clinical benefit and generally well-tolerated when dose regimens of 15 -35 mg/kg of body weight/day were HIV-1 replication [7, 8] . This effect was substantially enhanced when hydroxyurea was combined with nucleoside analogues, used over 6 months for the treatment of sickle cell anemia [12] . particularly ddI [9, 10] . The definitive mechanism responsible for the in vitro synergy between hydroxyurea and ddI remains
We undertook the present pilot clinical trial in an attempt to characterize the short-term in vivo antiretroviral effect of unclear. Hydroxyurea is known to inhibit the cellular enzyme ribonucleotide reductase [11] . This decreases the intracellular two doses of hydroxyurea in patients with advanced HIV disease who had been chronically treated with ddI therapy. pool of the dNTPs, preferentially dATP, which in turn can lead JID 1997; 175 (April) Eligibility criteria. Study participants were required to have at weeks 1-4, weeks 5-8, and weeks 9-12 for the baseline, hydroxyurea, and washout phases, respectively. The median had a minimum of 3 months of continuous ddI therapy before enrollment and to have received a stable dose of ddI for the previwithin-patient changes in plasma viremia were compared between the baseline and hydroxyurea phases for the entire study population ous 4 weeks. Other eligibility criteria included 100-350 CD4 cells/ mm 3 , age between 18 and 75 years, ú2.5 g/L white blood cells, with a Wilcoxon signed rank test. The difference in the change in median log 10 virus load between the baseline and hydroxyurea ú1.0 g/L granulocytes, ú100 g/L platelets, creatinine õ1.5 times the upper limit of normal, and transaminases and alkaline phosphaphases between treatment groups was tested with a Wilcoxon rank sum test. tase õ3 times the upper limit of normal. Patients with uncontrolled AIDS-defining illnesses, those who were actively receiving chemo-
The relationships between the change in mean plasma virus load from the baseline to the hydroxyurea phase and the duration of therapeutic agents, or those with active substance abuse were not eligible for the trial.
prior ddI therapy, the duration of prior zidovudine therapy, the CD4 cell count at baseline, and the level of plasma viremia at Subjects were required to have completed at least 3 of the first 4 baseline visits before progressing to the hydroxyurea phase of enrollment were assessed using a Spearman's correlation coefficient. Generalized estimating equation regression models, which the study. Concomitant therapy with any agents possibly active against HIV other than ddI was not allowed for the 12 weeks of allow for correlated observations within individuals [13] , were used to estimate the effects of each dose of hydroxyurea on plasma the study. Concomitant therapy with suppressive or prophylactic regimens against opportunistic infections was allowed as per convirus load and CD4 cell counts. Sample size estimation. On the basis of the known short-term temporary guidelines.
Study medications. Study participants were instructed to convariability of plasma virus load, we a priori identified a change in plasma virus load of §0.5 log 10 as indicative of a definite treatment tinue taking ddI orally at a dose of 200 mg twice daily on an empty stomach throughout the study period. During the hydroxyeffect [14] . Patients were said to have ''responded'' to therapy if the mean log 10 virus load during the hydroxyurea phase was at urea phase, study participants were instructed to add hydroxyurea to their regimen. Hydroxyurea (Hydrea; Bristol-Myers Squibb, least 0.5 log 10 copies lower than the mean virus load during the baseline phase. Wallingford, CT) was prescribed as 500-mg capsules. Patients were instructed to take hydroxyurea at least 3 h apart from ddI A sample size of 12 patients per arm was calculated as sufficient to detect a change of 0.5 log 10 copies/mL in the mean log virus dosing. Patients randomized to 500 mg/day took one 500-mg capsule daily and those assigned to 1000 mg/day took 500-mg capsules load between the baseline and hydroxyurea phases of the study, assuming the SD of the change in log virus load to be 0.5 log 10 twice daily.
Follow-up. Study participants were seen weekly for 12 weeks. copies/mL, a significance level of .05, and a power of 80%. Clinical assessment at each visit included a brief medical history, an assessment of compliance including pill count, a physical examination, and the administration of a targeted questionnaire regard-
Results
ing possible adverse effects related to study medications, including Thirty-one patients were enrolled between 15 March and 15 stomatitis, anorexia, nausea, vomiting, diarrhea, peripheral neurop-completed the remaining visits while receiving zidovudine
The average monthly log 10 plasma virus loads were calculated by taking the average of log 10 virus load measurements weekly monotherapy.
/ 9d21$$ap28 02-11-97 18:42:11 jinfa UC: J Infect droxyurea was used.
* Represents average of weeks 1 -4.
As shown in table 1, the median CD4 cell count at baseline † Data not available for 3 subjects (1 in 500-mg/day group, 2 in 1000-mg/ was 228 and 230 for the 500-and 1000-mg/day groups (P Å day group).
.61), respectively. As shown in figure 1 , CD4 cell counts remained stable during the hydroxyurea phase (P Å .45). A small but statistically significant decrease in CD4 cell counts was noted between washout and baseline -a total of 24 cells/mm 3 Figure 1 shows the weekly median change in virus load from baseline by treatment group. The median decline in log 10 for all patients (P Å .004). No statistical difference was found between dose groups (P Å .66). plasma viremia from the mean level during the baseline phase to the mean level during the hydroxyurea phase for the entire A total of 6 patients, 5 in the 500-mg/day and 1 in the 1000-mg/day groups, developed oral candidiasis during the study study group was 0.21 log 10 copies/mL (P Å .06). The median declines in log 10 plasma virus load for the 500-and 1000-mg/ period. One patient (in the 1000-mg/day group) developed Pneumocystis carinii pneumonia and another patient (in the day groups were 0.02 and 0.63 log 10 copies, respectively. These were statistically significantly different (P Å .03).
500-mg/day group) developed esophageal candidiasis during the washout phase. There were no statistically significant Eight of the 26 subjects had declines ú0.5 log 10 in mean plasma virus load while receiving hydroxyurea: 1 and 7 in the changes in weight or Karnofsky score during the study. No deaths occurred during the study period. 500-and 1000-mg/day groups, respectively (P Å .03). For 16 of the 26 subjects, the maximum difference between the mean All adverse events of any severity at least possibly related to hydroxyurea are listed in table 2. All adverse effects were plasma viremia at baseline and any single visit while receiving hydroxyurea was ú0.5 log 10 (7 in the 500-mg/day group, 9 in mild to moderate and did not preclude continued hydroxyurea dosing. No statistically significant association was found bethe 1000-mg/day group, P Å .69). For 9 of the 26 subjects, the maximum difference between the mean log 10 plasma virus tween any or all adverse events and dose of hydroxyurea. load during baseline and any single visit while receiving hydroxyurea was ú1.0 log 10 : 2 and 7 in the 500-and 1000-mg/ Discussion day groups, respectively (P Å .10).
Maximum changes from baseline in plasma virus load were Our data demonstrate a short-term statistically significant decrease in plasma viremia when 1000 mg of hydroxyurea was seen at week 5 (n Å 1), 6 (n Å 3), 7 (n Å 11), and 8 (n Å 8). Three patients (all in the low-dose arm) showed no decrease added to continued ddI therapy in HIV-infected persons with 100 -350 CD4 cells/mm 3 . We also demonstrated a dose-related in plasma virus load while receiving hydroxyurea. Maximum individual mean changes from baseline to weeks 5 -8 were effect of hydroxyurea on plasma viremia, with a median decline of 0.63 log 10 copies of HIV RNA/mL among patients receiving 00.6 log 10 in the 500-mg/day group and 02.4 log 10 in the 1000-mg/day group. 1000 mg/day and 0.02 log 10 copies of HIV RNA/mL among patients receiving 500 mg/day. Furthermore, despite extensive The change in mean plasma viremia levels from baseline was unrelated to the prior duration of ddI therapy (Spearman's prior antiretroviral therapy, including ddI, maximum mean plasma virus load decreases associated with the addition of correlation coefficient Å .06, P Å .78), prior duration of zidovudine therapy (Spearman's correlation coefficient Å .06, P Å hydroxyurea reached 02.4 log 10 copies of HIV RNA/mL with / 9d21$$ap28 02-11-97 18:42:11 jinfa UC: J Infect doses of 1000 mg/day. Finally, the rebound in plasma virus ddI therapy prior to enrollment and we allowed no other treatments with potential effect on plasma virus load during the load during the washout phase further supports the drug-related nature of the observed changes in plasma virus load while study to avoid the potential confounding effect of such cointerventions. Also, we monitored patients during the 1-month receiving hydroxyurea treatment.
Our data provide controlled evidence of an in vivo antiretbaseline period while receiving ddI to ensure the absence of any ongoing effects of this therapy on plasma virus load. roviral effect of hydroxyurea. Previous reports consisted of in vitro studies or limited uncontrolled patient series [15 -18] .
While our eligibility criteria minimized baseline variability in plasma virus load, they also generated a conservative bias Based on the available evidence, we limited our study to the use of hydroxyurea in the context of ddI therapy. Further studregarding the antiretroviral effect of hydroxyurea. Prior exposure to ddI and zidovudine is likely to have minimized treaties will be required to clarify whether the in vivo antiretroviral effect of hydroxyurea is also present within the context of other ment response. In this context, if the ability of hydroxyurea to affect virus load is mediated through the enhancement of drug combinations.
Our patient population was predefined as to minimize known ddATP uptake, as previously suggested, extensive prior ddI therapy may have minimized therapeutic response in our setting sources of short-term variability in plasma virus load. Hence, we selected patients who had advanced disease but were clini- [9] . It is noteworthy that HIV resistance to ddI, as demonstrated by a point mutation at codon 74 of the HIV reverse trancally stable. Further, we required a minimum of 3 months of of nucleoside analogues are currently recommended for the treatment of HIV infection [5, 6, 23] . In this context, the potential adjunctive effect of hydroxyurea merits further evaluation. scriptase, has been shown to occur in 56% of patients after 6
In summary, our results demonstrate a substantial decrease months of ddI therapy [19] . Alternatively, zidovudine resisin plasma virus load when hydroxyurea is administered as tance may also have affected ddI response as shown in ACTG adjunctive therapy to ddI among HIV-infected persons with protocol 116B/117. Although we did not screen for point muta-100 -350 CD4 cells/mm 3 . We demonstrated a median decline tions at codon 74 or zidovudine resistance at baseline, it is in plasma viremia of 0.63 log 10 HIV RNA copies/mL when a likely that this was present in a number of subjects given the dose of 1000 mg/day hydroxyurea was used. Maximum mean extensive prior exposure to zidovudine and ddI in our study virus load decline reached 02.4 log 10 HIV RNA copies/mL population.
with this same dose. CD4 cell counts, however, did not change Plasma viremia decreases of ú0.5 log 10 copies of HIV RNA/ significantly while patients were receiving hydroxyurea. HymL are generally accepted as indicative of a treatment effect droxyurea was well-tolerated in this patient group. Our findings [14] . Recently, Yerly et al. [20] reported that a decrease in suggest that the potential clinical role of hydroxyurea as adplasma viremia between 0.63 and 0.82 log 10 HIV RNA copies/ junctive therapy should be further evaluated. mL after 1 month of ddI monotherapy was predictive of improved survival, independent of an initial diagnosis of AIDS or baseline CD4 cell counts. Interestingly, our data demonstrate
